PCS499

DRUG3 trials

Sponsors

Processa Pharmaceuticals

Conditions

HealthyNecrobiosis Lipoidica

Phase 1

Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects

CompletedNCT03836222

Processa PharmaceuticalsHealthy

Start: 2018-02-26End: 2018-06-04Updated: 2019-02-12

Phase 2

A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

CompletedNCT03698864

Processa PharmaceuticalsNecrobiosis Lipoidica

Start: 2018-11-07End: 2020-02-25Updated: 2022-10-03

A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

TerminatedNCT04800562

Processa PharmaceuticalsNecrobiosis Lipoidica

Start: 2021-04-12End: 2023-04-14Updated: 2023-08-03

Related Papers

Deuterated Pentoxifylline Analog in the Treatment of Necrobiosis Lipoidica: A Nonrandomized Clinical Trial.

2026-04-29